

REMARKS

Prior to entry of this amendment, claims 14, 16-27 and 30 were pending. No new claims are added and no claims are canceled. Thus, after entry of this amendment, **claims 14, 16-27 and 30 will still be pending.**

Claim 22 is amended herein to read “an immunogenic *lipidated* fragment” as suggested by the Examiner. No new matter has been introduced by this amendment.

EXAMINER INTERVIEW

Applicants thank Examiner Swartz for the courtesy of a brief telephone interview with Applicants’ representative, Jodi L. Connolly, on June 30, 2009. During the telephone interview, the rejection of claim 22 was discussed. Examiner Swartz indicated that amending the claim to read “an immunogenic lipidated fragment thereof” would be sufficient to overcome the pending rejection under 35 U.S.C. §112, second paragraph.

REJECTION UNDER 35 U.S.C. §112, SECOND PARAGRAPH

Claims 22-24 remain rejected under 35 U.S.C. §112, second paragraph, as allegedly being indefinite for the reasons of record. Specifically, the Office alleges that it is unclear if the immunogenic fragment is lipidated. In response, claim 22 is amended herein to read “an immunogenic *lipidated* fragment” as suggested by the Examiner. Accordingly, Applicants request withdrawal of this rejection under 35 U.S.C. §112, second paragraph.

CONCLUDING STATEMENT

Applicants believe that all pending claims are now in a condition for allowance. Should the Examiner have further questions or comments with respect to examination of this case, it is respectfully requested that the Examiner telephone the undersigned so that further examination of this application can be expedited.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By /Jodi L. Connolly/
Jodi L. Connolly, Ph.D.
Registration No. 54,044